Patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) that is PD-L1 positive (CPS > 1) and who have not received prior systemic therapy for their advanced disease.Adequate bone marrow function. Adequate renal and liver function. Adequate ECOG performance status.
Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.History of (non-infectious) pneumonitis that required steroids or has current pneumonitis. Prior treatment with any anti-CD47 or anti-SIRPα agent. Prior treatment with anti-PD-1 or PD-L1.